At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRBP Corbus Pharmaceuticals
Market Closed 12-20 16:00:00 EST
13.00
-0.33
-2.48%
盘后13.00
+0.000.00%
18:24 EST
High13.46Low12.93Vol1.01M
Open13.14D1 Closing13.33Amplitude3.98%
Mkt Cap158.33MTradable Cap100.85MTotal Shares12.18M
T/O13.25MT/O Rate13.08%Tradable Shares7.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains
Dow Jones  ·  12-20
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Corbus Pharmaceuticals (CRBP) and Fortrea Holdings Inc. (FTRE)
TIPRANKS  ·  12-17
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Corbus Pharmaceuticals (CRBP) and Fortrea Holdings Inc. (FTRE)
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors
Dow Jones  ·  12-17
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors
Corbus Pharmaceuticals Holdings Inc. Stock Remains Steady Friday, Underperforms Market
Dow Jones  ·  12-14
Corbus Pharmaceuticals Holdings Inc. Stock Remains Steady Friday, Underperforms Market
Promising Potential of Corbus Pharmaceuticals: Buy Rating Reinforced by Key Assets and Strategic Focus
TIPRANKS  ·  12-12
Promising Potential of Corbus Pharmaceuticals: Buy Rating Reinforced by Key Assets and Strategic Focus
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors
Dow Jones  ·  12-12
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors
Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day
Dow Jones  ·  12-10
Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day
Corbus Pharmaceuticals announces dosing of first patient in FIH study of CRB-601
TIPRANKS  ·  12-09
Corbus Pharmaceuticals announces dosing of first patient in FIH study of CRB-601
Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-in-Human Study of Crb-601 to Treat Patients With Advanced Solid Tumors
THOMSON REUTERS  ·  12-09
Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-in-Human Study of Crb-601 to Treat Patients With Advanced Solid Tumors
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
GlobeNewswire  ·  12-09
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors
Dow Jones  ·  12-05
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors
Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
Insider Monkey  ·  12-05
Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
Corbus Pharmaceuticals' CRB-701 Gets FDA Fast Track Designation for Treatment of Cervical Cancer
MT Newswires Live  ·  12-03
Corbus Pharmaceuticals' CRB-701 Gets FDA Fast Track Designation for Treatment of Cervical Cancer
Corbus Pharmaceuticals Advances with FDA Fast Track Designation
TIPRANKS  ·  12-03
Corbus Pharmaceuticals Advances with FDA Fast Track Designation
Corbus Pharmaceuticals Receives Fast Track from FDA for Cervical Cancer Treatment
Dow Jones  ·  12-03
Corbus Pharmaceuticals Receives Fast Track from FDA for Cervical Cancer Treatment
Corbus Pharmaceuticals announces U.S. FDA granted FTD to CRB-701
TIPRANKS  ·  12-03
Corbus Pharmaceuticals announces U.S. FDA granted FTD to CRB-701
Corbus Pharmaceuticals Holdings Inc - First Data From Dose Escalation Study Expected in Q1 2025
THOMSON REUTERS  ·  12-03
Corbus Pharmaceuticals Holdings Inc - First Data From Dose Escalation Study Expected in Q1 2025
FDA Grants Fast Track Designation to Crb-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
THOMSON REUTERS  ·  12-03
FDA Grants Fast Track Designation to Crb-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
GlobeNewswire  ·  12-03
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
Corbus Pharmaceuticals Holdings Inc. Stock Rises Monday, Still Underperforms Market
Dow Jones  ·  12-03
Corbus Pharmaceuticals Holdings Inc. Stock Rises Monday, Still Underperforms Market

Introduction

Company Name.
Corbus Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Issue price:
--